Our Take
AbbVie is buying clinical-stage assets at peak biotech multiples, betting that zumilokibart's extended half-life and multi-indication pipeline justify mega-blockbuster valuations before Phase III data arrives.
Why it matters
Big pharma is consolidating the immunology space as blockbuster successes like Skyrizi and Stelara prove the commercial thesis. Deal activity in immunology trials has nearly doubled since 2021, and pharma dealmaking hit $65bn in Q1 2026 alone.
Do this week
Portfolio managers: stress-test your competitive positioning in IL-13 and OX40 agonists before Q3 2026 when this deal closes, as AbbVie's scale and existing immunology distribution will reshape market dynamics.
AbbVie Acquires Apogee for $10.9B in Cash
AbbVie has agreed to buy Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash. The deal represents a near 50% premium on Apogee's stock price as of June 18, 2025, and is expected to close in Q3 2026. At the core of the acquisition is zumilokibart (formerly APG777), an injectable anti-IL-13 therapy designed with an extended half-life to support quarterly or biannual maintenance dosing in patients.
Zumilokibart is currently in clinical development for atopic dermatitis, with a Phase III trial expected to start in the second half of 2026. Apogee is also exploring the drug in asthma and eosinophilic oesophagitis, with trials slated to begin in 2026 and 2027. AbbVie will also gain access to combination therapies pairing zumilokibart with OX40 ligand binding (APG279 for atopic dermatitis) and TSLP inhibitor activity (APG273 for asthma and COPD).
AbbVie characterizes zumilokibart as holding "mega-blockbuster peak sales potential" based on what it calls "best-in-category" efficacy and dosing convenience. The deal doubles down on AbbVie's existing immunology franchise, which includes Skyrizi (risankizumab), Rinvoq (upadacitinib), and Humira (adalimumab).
Immunology Deal Velocity Reflects Market Confidence
This acquisition is one of several high-profile bets on immunology by large pharma firms. Biogen acquired RayThera, Eli Lilly struck a development deal with Innovent Biologics, and GSK took over RAPT Therapeutics. The activity reflects proven commercial success: immunology trials have nearly doubled their proportion of overall trial initiations between 2021 and 2025 (per Clinical Trials Arena, cited in the source).
Industry sentiment supports the spending spree. A survey of 157 pharmaceutical executives found 55% are optimistic or very optimistic about industry growth over the next year (per GlobalData's State of the Biopharmaceutical Industry 2026 report). Life sciences and pharma dealmaking exceeded $65 billion in Q1 2026 alone, the highest single-quarter total since Q1 2020 (per PwC, cited in the source).
For AbbVie, the move shores up its franchise as anti-IL-13 and anti-IL-4 therapies proliferate. The company is acquiring clinical-stage assets at a premium valuation, betting that zumilokibart's dosing profile and multi-indication pipeline will command market share once Phase III data arrives.
What Competitors and Investors Should Monitor
Investors should track zumilokibart's Phase III atopic dermatitis trial starting in H2 2026. The drug's quarterly or biannual dosing is a genuine differentiation claim if efficacy matches or exceeds existing anti-IL-13 or anti-IL-4 therapies, but this remains unproven in head-to-head comparison. No independent benchmark data for zumilokibart versus competitors like dupilumab or lebrikizumab is yet available.
Competitors in IL-13 and OX40 space should assume AbbVie will aggressively deploy its sales force and existing payer relationships behind zumilokibart once approved. The deal closes Q3 2026, leaving roughly 12-18 months to establish position or accelerate rival molecules before AbbVie's commercial machine engages.
Portfolio companies and biotech boards tracking immunology M&A multiples should note that AbbVie paid a near-50% premium on stock price for early-stage clinical assets. This signals continued willingness to pay for de-risked platforms and extended-half-life biologics, but clinical data remains the gating factor for approval and peak sales assumptions.